Dupixent (dupilumab) - Sanofi, Regeneron
Clinically Meaningful Patient Reported Outcome Improvements with Dupilumab vs Placebo in Allergic Fungal Rhinosinusitis: LIBERTY-AIMS (ACAAI 2026) - Oct 28, 2026 - Abstract #R351; Pres time: Nov 14, 2026; 11:45 AM - 01:00 PM; Location: Phoenix Convention Center • North Halls 4–6 (Lower Level); Monitor 22; No abstract available 
Clinical • Patient reported outcomes • Otorhinolaryngology • Respiratory Diseases • Sinusitis
https://annualmeeting.acaai.org/2026/submit_abstract.cfm
 
Oct 28, 2026
 
Prev Next